DaVita Lifts Floor Of 2026 Profit Outlook After A $62 Million China Impairment
Adjusted operating income was $561 million in the third quarter, while cash flow fell well below a year earlier.
DaVita, the kidney-care company built around dialysis, raised the low end of its 2026 profit forecast on Thursday even as a $62 million non-cash China impairment cut third-quarter earnings to $3.40 a share, or $3.82 on an adjusted basis. Revenue was $3.578 billion.
China charge cuts into the quarter
The impairment pulled operating income to $499 million, a 14.0% margin, from $579 million and 16.3% in the second quarter. Adjusted operating income, which excludes the charge, was $561 million. Adjusted earnings per share of $3.82 compared with $4.02 in the second quarter.
The company said the charge was offset by a $1 million tax benefit and a $34 million credit to noncontrolling interests, leaving a $27 million hit to net income attributable to DaVita.
International posted an operating loss of $16 million against a $25 million profit in the second quarter. Integrated kidney care income fell to $4 million from $40 million.
Cash flow trails last year
Operating cash flow was $519 million, up from $490 million in the second quarter but below $842 million a year earlier. Free cash flow was $276 million, against $256 million in the second quarter and $604 million a year earlier.
DaVita narrowed its 2026 outlook. Adjusted operating income is now forecast at $2,175 million to $2,250 million, from $2,150 million to $2,250 million. Adjusted earnings per share is guided to $14.30 to $15.20, from $14.10 to $15.20. The free cash flow range stays at $1,000 million to $1,250 million.
Buybacks, debt and patient growth
DaVita spent $863 million repurchasing 5,837 thousand shares over nine months, including $111 million in the third quarter at an average $186.21 a share. Since September 30 through October 27, it bought another 0.5 million shares for $87 million. Shareholders' equity remains in deficit.
Debt was $10,832 million, a leverage ratio of 3.38x against a 5.00x covenant maximum. Normalized non-acquired treatment growth was 0.4% from a year earlier.
The U.S. dialysis business, the company's largest, earned $544 million in the quarter. DaVita counted about 80,800 patients in risk-based integrated care arrangements at September 30, up from 64,900 at June 30, representing about $6.4 billion in annualized medical spend.
DaVita holds its earnings call at 5:00 p.m. Eastern on Thursday.
Sources
- 8-K Filing — DAVITA INC. (DVA) — SEC EDGAR
- Exhibit dva93026ex991.htm — DAVITA INC. 8-K exhibit — SEC EDGAR
- DaVita Non-GAAP EPS of $3.82 beats by $0.25, revenue of $3.57B beats by $50M (DVA:NYSE) | Seeking Alpha — seekingalpha.com